Cargando…
肺腺癌患者在Atezolizumab治疗过程中出现假性进展的案例报道
Lung cancer is the most common cause of cancer-related death worldwide. There are two classes of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC represents approximately 85% of all lung cancer cases. Immune checkpoint inhibitors (ICIPs) are a class of inhibit...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580083/ https://www.ncbi.nlm.nih.gov/pubmed/31196374 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.10 |